MarketMoodz
FDA approves Opdivo plus chemo for untreated Hodgkin lymphoma
The FDA cleared Bristol Myers Squibb's Opdivo (nivolumab) with chemotherapy (AVD) as first-line treatment for adults and patients aged 12+ with untreated Stage III/IV classical Hodgkin lymphoma. The move broadens Opdivo's frontline footprint and intensifies the PD-1 competition with Merck's Keytruda. In CA209-8UT, progression-free survival favored nivolumab+AVD with a hazard ratio of 0.42, though final publication details remain pending.
Key Takeaways
- FDA approves nivolumab+AVD as first-line therapy for untreated Stage III/IV cHL in adults and patients 12+
- CA209-8UT shows PFS HR of 0.42 for nivolumab+AVD vs brentuximab+AVD
- Deaths at 36.7 months: 1.8% (nivolumab+AVD) vs 3.4% (brentuximab+AVD)
- Potential Opdivo revenue impact and short-term stock reaction amid broader PD-1 competition
People Involved
- No specific individuals mentioned
Entities Involved
- Bristol Myers Squibb (BMY) Pharmaceutical company behind Opdivo
- Merck & Co. (MRK) Manufacturer of Keytruda, Opdivo competitor
- Seagen (formerly Seattle Genetics) Co-developer of brentuximab vedotin (ADCETRIS)
- Takeda Pharmaceutical Co-developer/partner for brentuximab vedotin
MarketMoodz Analysis
This approval expands Opdivo’s addressable patient pool in Hodgkin lymphoma, potentially lifting first-line exposure and near-term top-line opportunities for BMS. The CA209-8UT PFS signal of 0.42 suggests a meaningful progression-free advantage for nivolumab+AVD versus a brentuximab-based regimen, which could influence payer decisions and patient access if the data hold in full publication.
Historically, PD-1 inhibitors have carved out a niche in relapsed/refractory HL; extending their use to frontline settings marks a strategic shift toward combining immunotherapy with standard chemotherapy in hematologic cancers. The competitive dynamic with Keytruda will hinge on broader efficacy, durability, and real-world access across healthcare systems. Investors should watch for full data disclosures, regulatory labeling nuances, and payer coverage as the program advances.
What to watch next: final publication of CA209-8UT results, FDA briefing materials for any label expansion details, and how payer policies address frontline nivolumab+AVD across different markets. Additional pipeline readthroughs for BMS’s immunotherapy franchise will matter as the company balances new approvals with competitive pressure.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial